Arch Scientists Publish Data on the Efficacy and Mechanism of Action of Lead Drug Candidate AB569
TORONTO, ONTARIO--(Marketwired - March 1, 2016) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today that Dr. Daniel Hassett's team at the University of Cincinnati College of Medicine, and its collaborators, have published details regarding the efficacy of AB569 in killing the pathogenic bacterium Pseudomonas aeruginosa (P. aeruginosa) in the peer-reviewed journal Frontiers in Microbiology. The findings indicate that low doses of acidified nitrite and EDTA (active ingredients of AB569) are highly effective at killing P. aeruginosa. In addition, the article provides information on the drug's mechanism of action.
Arch Biopartners Submits Orphan Drug Application for AB569 to European Medicines Agency
TORONTO, ONTARIO--(Marketwired - Feb. 3, 2016) - Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced they have submitted an application for orphan drug designation to the European Medicines Authority (EMA) for AB569 in the treatment of Pseudomonasaeruginosa (P. aeruginosa) pulmonary infections in patients with cystic fibrosis.
Arch Biopartners, McMaster Scientists, Expand MetaMx Collaboration with Mitacs Award
TORONTO, ONTARIO--(Marketwired - Jan. 6, 2016) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced a Mitacs fellowship with McMaster University for its MetaMx product, a library of synthetic peptides that target and image brain tumour initiating cells.